The long-awaited news came from the American company about the fight against covid-19...

The vaccine of the American laboratory "Moderna", co-financed by the US government, will enter the third and final phase of clinical trials at 30,000 volunteers in July, the company announced today. This is the crucial stage of the test, which will make it possible to see, on a large scale, healthy people if the vaccine is more effective than a drug to prevent coronavirus contamination. The protocol has been completed with the US Medicines Agency (FDA) and the test will be conducted in collaboration with the National Institutes of Health (NIH). The Washington-funded American biotech company "Moderna" announced preliminary but very encouraging results for its experimental vaccine to eight volunteers. In eight people, the experimental vaccine called mRNA-1273 gave an immune response similar to that seen in people who are naturally infected with the virus that causes COVID-19. If the dose chosen for the tests (100 micrograms) is effective, "Moderna" has planned to be able to produce 500 million doses a year and possibly up to a billion. It is too early to predict the future of this vaccine, based on a technology called RNA message that has not yet proven its effectiveness. The technology aims to provide the body with the genetic information needed to activate preventive protection against coronavirus.